

	Neoadjuvant/Surgical	Adjuvant	Metastatic	Brain Mets
Melanoma	<ul style="list-style-type: none"> <li>• <b>S2015 (Doug/Ollila):</b> A Phase III, Multi-Centre, Multi-National Randomized Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma <b>(temporary closure to accrual)</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>R3767-ONC-2055 (Doug/Collichio):</b> A Phase 3 trial of Fianlimab (ANTI-LAG-3) and Cemiplimab versus Pembrolizumab in the adjuvant setting in patients with completely resected high-risk melanoma</li> </ul>	<ul style="list-style-type: none"> <li>• <b>LCCC1736 (Doug/Moschos)</b> A Phase I Trial of Ulixertinib (BVD-523) in Combination with Palbociclib in Patients with Advanced Solid Tumors with Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant Melanoma <b>Histologically confirmed unresectable stage III or stage IV melanoma with the following additional eligibility requirements:</b> -Molecular profiling documenting any of the following genetic aberrations: <i>NRASG12/G13/Q61, KRASG12/G13, HRASG12/G13</i>, any amplifications of the <i>NRAS, KRAS</i>, or <i>HRAS</i> genes - Documented disease refractory to at least one PD1/PD-L1 inhibitor - Previously received treatment with Ipilimumab</li> <li>• <b>EA6192 (Doug/Moschos)</b> A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)</li> </ul>	<ul style="list-style-type: none"> <li>• <b>A071701 (Amalia/Rauf)</b> Genomically-guided treatment trial in brain metastases <ul style="list-style-type: none"> <li>- This is a prospective Phase 2 study evaluating the efficacy of a CDK, PI3K or NTRK/ROS1 inhibitor in patients with progressive brain metastases harboring the alterations predicting sensitivity to each of these inhibitors</li> </ul> <b>For melanoma, patients must have progressed after prior immune checkpoint blockade or for BRAF positive melanoma, BRAF/MEK inhibitors.</b> </li> </ul>
Cutaneous Sarcoma				
Merkel Cell Carcinoma				
TSHS, Phase I, Other	<ul style="list-style-type: none"> <li>• <b>PBI-MST-01 (Sheth/Olivia)</b> <i>A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients With Solid Tumors</i></li> </ul>		<ul style="list-style-type: none"> <li>• <b>NX-1607-101 (Weiss/Elizabeth)</b> <i>A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types. (Recurrent and either metastatic or unresectable melanoma)</i></li> <li>• <b>TAPUR (Shetal Patel/Elizabeth)</b> Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)</li> </ul>	<p>Research Contact (Coordinator/pager #)</p> <p><b>Melanoma Pod:</b> Melissa Flores – 216-2481 Margie Edwards – 347-0593 Doug Whelan - 347-0491</p> <p><b>Phase 1</b> Melissa Flores - 216-2481 Olivia Gorman - (919) 393-0083 Eliaabeth Schwabe – <a href="mailto:elizabeth_schwabe@med.unc.edu">elizabeth_schwabe@med.unc.edu</a></p> <p><b>Neuro Pod (LCCC1636):</b> Camisha Johnson - 919-393-2713 Amalia Postier – <a href="mailto:amalia_postier@med.unc.edu">amalia_postier@med.unc.edu</a></p>

			<b>Link to available cohorts:</b> <a href="https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/research-data/documents/Public-facing_Cohort_Report.pdf">https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/research-data/documents/Public-facing_Cohort_Report.pdf</a>	
--	--	--	---	--